CANY
ESPR

Caxton Associates (New York)’s Esperion Therapeutics ESPR Stock Holding History

Caxton Associates (New York)’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-33,230
Closed -$207K – 532
2022
Q4 		$207K Buy
+33,230
New +$238K 0.01% 375
2022
Q3 		– Sell
-19,768
Closed -$126K – 531
2022
Q2 		$126K Buy
+19,768
New +$112K 0.01% 501

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Caxton Associates (New York)'s ESPR Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 33,230 shares — an estimated $207K sold.

Caxton Associates (New York) first reported a position in ESPR in Q2 2022 and held it in 2 quarters. The position peaked at $207K in Q4 2022. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • Caxton Associates (New York) reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 33,230 Esperion Therapeutics shares in Q1 2023, an estimated $207K.
  • Caxton Associates (New York) first reported a position in Esperion Therapeutics in Q2 2022 and held it in 2 quarters.
  • Caxton Associates (New York)'s Esperion Therapeutics position peaked at $207K in Q4 2022.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.